In recent years, there has been mounting evidence that multiple metastases in the brain can be successfully treated with stereotactic radiosurgery (SRS). Evidence has also accrued to show that a single lung, spine, or other extracranial met can often be successfully treated—with durable results—using stereotactic ablative radiotherapy (SABR). But what about multiple metastases outside the brain? Until recently, these patients were typically offered palliative treatments, such as chemotherapy. The ongoing SABR-COMET randomized trial, which looks at SABR for the comprehensive treatment of oligometastatic cancer, appears to suggest a change in paradigm of managing these patients. At ASTRO this year, David A. Palma, MD, PhD, presented long-term results of the study. He reported that the magnitude of benefit of SABR was greater than previously reported, and durable beyond five years.¹ In this webinar, Dr. Palma talks with moderator Robert Timmerman, MD, about the SABR-COMET trial, the latest results, and the implications for the treatment of patients with multiple sites of metastasis. ¹Palma DA, Olson RA, Harrow S et al. Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Randomized Trial. International Journal of Radiation Oncology, Biology, Physics, Vol. 108, Issue 3, Supplement.
Sed ut perspiciatis unde omnis iste natus error sit voluptatem!
Nemo enim ipsam voluptatem quia voluptas sit odit aut fugit!
Ut enim ad minima veniam, quis nostrum exercitationem ullam!
Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia non numquam eius modi tempora incidunt ut labore et dolore magnam aliquam quaerat voluptatem.
Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam, nisi ut aliquid ex ea commodi consequatur? Quis autem vel eum iure reprehenderit qui in ea voluptate velit
Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia non numquam eius modi tempora incidunt ut labore et dolore magnam aliquam quaerat voluptatem.